NEGXF (NexgenRx) Payments of Debt: $-0.07 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEGXF NexgenRx Inc NEGXF
40 GF Score
Price $0.33
GF Value $0.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx Payments of Debt?

NexgenRx NEGXF 40 Payments of Debt is $-0.07 Mil as of Mar. 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review.

NexgenRx's Payments of Debt for the three months ended in Mar. 2026 was $-0.02 Mil.

NexgenRx's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.07 Mil.

NexgenRx Payments of Debt Related Terms

NexgenRx Payments of Debt Historical Data

* Premium members only.

The historical data trend for NexgenRx's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx Payments of Debt Chart

NexgenRx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.63 -0.15 -0.06 -0.07 -0.08

NexgenRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.01 -0.02
NEGXF
40GF Score
NexgenRx Inc NEGXF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NexgenRx Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.07 Mil mean?
NexgenRx (NEGXF) has a Payments of Debt of $-0.07 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NexgenRx and its competitors.
Is NexgenRx's Payments of Debt too high?
NexgenRx's current Payments of Debt is $-0.07 Mil. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Payments of Debt compare to VEEV and BTSG?
NexgenRx's Payments of Debt of $-0.07 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Healthcare Providers & Services company?
A good Payments of Debt depends on the Healthcare Providers & Services industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on NexgenRx and its competitors. NexgenRx's current Payments of Debt is $-0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current Payments of Debt is $-0.07 Mil. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Payments of Debt is $-0.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • Payments of Debt: $-0.07 Mil
  • GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score

Get the complete analysis for NEGXF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.27
GF Value